A double-blind placebo-controlled trial of topiramate treatment for essential tremor.
The safety and efficacy of topiramate (400 mg/d or maximum tolerated dose) as monotherapy or adjunctive treatment of essential tremor were investigated in a placebo-controlled, crossover study (n = 24). Topiramate resulted in significantly greater reductions from baseline based on normalized scores for a clinical rating of tremor location/severity, specific motor tasks/functional disabilities, and tremor-resultant functional disabilities. Most common adverse events were appetite suppression/weight loss and paresthesias.
Connor
Gregory S
GS
Headache and Neurological Center of Oklahoma, Tulsa, OK 74136, USA.
D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D020329:Essential Tremor / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000008:administration & dosage* / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077236:Topiramate; D016896:Treatment Outcome
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose